Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out ...

MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

New World Health Organisation (WHO) recommendations for the use of long-acting HIV prevention and treatment are a welcome boost in the global efforts to end ...